

TDMs No. 20311 - 02

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 06/30/2009

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C Number: C20311
Lock Date: 12/01/2008
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Female
TDMSE Version: 2.1.0

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Disposition Summary						
Animals Initially in Study	48	47	48	48	51	48
Early Deaths						
Moribund Sacrifice	8	7	3	4	8	9
Natural Death	2	1	3	3	2	3
Survivors						
Moribund Sacrifice		3	2	1	2	2
Natural Death		1			1	
Terminal Sacrifice	37	28	38	35	35	32
Harvest	1	7	2	5	3	2
Animals Examined Microscopically	48	47	47	48	51	48

ALIMENTARY SYSTEM

Esophagus	(47)	(47)	(46)	(48)	(50)	(47)
Gallbladder	(46)	(45)	(44)	(46)	(48)	(45)
Intestine Large, Cecum	(46)	(46)	(46)	(46)	(49)	(46)
Sarcoma						
Intestine Large, Colon	(46)	(46)	(46)	(46)	(50)	(46)
Intestine Large, Rectum	(46)	(46)	(46)	(46)	(50)	(46)
Sarcoma, Metastatic, Skin						
Intestine Small, Duodenum	(46)	(47)	(45)	(45)	(49)	(45)
Adenoma		1 (2%)	1 (2%)			2 (4%)
Intestine Small, Ileum	(46)	(46)	(46)	(46)	(50)	(46)
Polyp Adenomatous					1 (2%)	
Intestine Small, Jejunum	(46)	(45)	(46)	(46)	(48)	(46)
Adenoma						
Liver	(47)	(46)	(46)	(48)	(50)	(47)
Hemangiosarcoma			1 (2%)			
Hemangiosarcoma, Metastatic, Spleen				1 (2%)		
Hepatocellular Adenoma	4 (9%)	3 (7%)	6 (13%)	4 (8%)	2 (4%)	3 (6%)
Hepatocellular Adenoma, Multiple	1 (2%)	1 (2%)	2 (4%)			1 (2%)
Hepatocellular Carcinoma	1 (2%)	2 (4%)	3 (7%)	2 (4%)	6 (12%)	2 (4%)
Hepatocellular Carcinoma, Multiple						
Mesentery	(8)	(4)	(11)	(6)	(7)	(11)
Pancreas	(46)	(46)	(46)	(48)	(49)	(46)
Fibrous Histiocytoma						

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Sarcoma, Metastatic, Skin						
Salivary Glands	(47)	(45)	(46)	(48)	(50)	(46)
Hemangiosarcoma						
Stomach, Forestomach	(46)	(47)	(45)	(47)	(50)	(46)
Squamous Cell Papilloma			1 (2%)		2 (4%)	
Squamous Cell Papilloma, Multiple				1 (2%)		
Stomach, Glandular	(46)	(46)	(45)	(46)	(48)	(46)
Adenoma		1 (2%)				
CARDIOVASCULAR SYSTEM						
Blood Vessel	(48)	(46)	(46)	(48)	(49)	(45)
Heart	(47)	(47)	(46)	(48)	(50)	(48)
Carcinoma, Metastatic, Lung					1 (2%)	
ENDOCRINE SYSTEM						
Adrenal Cortex	(47)	(47)	(46)	(47)	(50)	(47)
Adenoma						
Subcapsular, Adenoma					1 (2%)	
Adrenal Medulla	(46)	(45)	(43)	(46)	(47)	(46)
Pheochromocytoma Benign						
Islets, Pancreatic	(47)	(46)	(46)	(48)	(49)	(46)
Adenoma	1 (2%)	1 (2%)	2 (4%)			
Carcinoma						
Parathyroid Gland	(45)	(44)	(40)	(38)	(40)	(36)
Pituitary Gland	(46)	(44)	(44)	(46)	(49)	(45)
Pars Distalis, Adenoma	3 (7%)	4 (9%)	4 (9%)	6 (13%)	7 (14%)	1 (2%)
Pars Intermedia, Adenoma						1 (2%)
Thyroid Gland	(47)	(46)	(46)	(47)	(50)	(46)
C-cell, Carcinoma						
Follicular Cell, Adenoma	3 (6%)		1 (2%)			1 (2%)
Follicular Cell, Carcinoma	1 (2%)					
GENERAL BODY SYSTEM						
Tissue NOS	(1)	(2)	(1)	(1)	(2)	(0)
Abdominal, Fibrosarcoma, Metastatic, Skin		1 (50%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Abdominal, Fibrous Histiocytoma						
Abdominal, Sarcoma					1 (50%)	
Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung					1 (50%)	
Mediastinum, Carcinoma, Metastatic, Lung						
Thoracic, Sarcoma			1 (100%)			
GENITAL SYSTEM						
Clitoral Gland	(46)	(43)	(44)	(44)	(49)	(44)
Ovary	(47)	(45)	(45)	(48)	(50)	(43)
Cystadenoma	1 (2%)	1 (2%)		2 (4%)	2 (4%)	1 (2%)
Granulosa Cell Tumor Benign						
Hemangioma	1 (2%)	1 (2%)			1 (2%)	
Hemangiosarcoma					1 (2%)	
Luteoma						
Sertoli Cell Tumor Benign				1 (2%)		
Tubulostromal Adenoma						
Yolk Sac Carcinoma						
Uterus	(47)	(47)	(46)	(48)	(50)	(46)
Adenocarcinoma			1 (2%)			
Granular Cell Tumor Benign						
Hemangiosarcoma					1 (2%)	
Polyp Stromal		1 (2%)		1 (2%)		
Sarcoma						
Sarcoma Stromal		1 (2%)				
HEMATOPOIETIC SYSTEM						
Bone Marrow	(46)	(47)	(46)	(46)	(50)	(46)
Hemangiosarcoma	1 (2%)				1 (2%)	
Hemangiosarcoma, Metastatic, Spleen				2 (4%)		
Lymph Node	(8)	(12)	(5)	(5)	(10)	(9)
Lumbar, Fibrous Histiocytoma						
Mediastinal, Carcinoma, Metastatic, Lung					1 (10%)	
Lymph Node, Mandibular	(47)	(44)	(46)	(48)	(49)	(45)
Adenocarcinoma, Metastatic, Harderian Gland						

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Lymph Node, Mesenteric Adenocarcinoma, Metastatic, Mammary Gland	(45)	(46)	(45)	(45)	(48)	(46)
Fibrous Histiocytoma				1 (2%)		
Hemangiosarcoma, Metastatic, Salivary Glands						
Sarcoma			1 (2%)			
Spleen	(47)	(47)	(46)	(47)	(50)	(48)
Hemangiosarcoma				3 (6%)	4 (8%)	1 (2%)
Hemangiosarcoma, Metastatic, Salivary Glands						
Hemangiosarcoma, Metastatic, Skin						
Thymus	(46)	(42)	(44)	(45)	(47)	(43)
Carcinoma, Metastatic, Lung				1 (2%)	1 (2%)	
Thymoma Benign		1 (2%)				
INTEGUMENTARY SYSTEM						
Mammary Gland	(47)	(46)	(45)	(45)	(50)	(45)
Adenocarcinoma	3 (6%)	1 (2%)	1 (2%)	2 (4%)	1 (2%)	3 (7%)
Adenoma					1 (2%)	
Skin	(48)	(47)	(46)	(48)	(50)	(46)
Hemangiosarcoma						1 (2%)
Trichoepithelioma						
Ear, Hemangiosarcoma				1 (2%)		
Subcutaneous Tissue, Fibrosarcoma	3 (6%)	2 (4%)		2 (4%)	4 (8%)	2 (4%)
Subcutaneous Tissue, Hemangioma						
Subcutaneous Tissue, Lipoma						
Subcutaneous Tissue, Sarcoma	3 (6%)	2 (4%)				
MUSCULOSKELETAL SYSTEM						
Bone, Femur	(48)	(47)	(47)	(48)	(51)	(48)
Osteosarcoma						
Skeletal Muscle	(0)	(0)	(0)	(1)	(1)	(1)
Fibrosarcoma, Metastatic, Skin						
Hemangiosarcoma, Metastatic, Spleen				1 (100%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
NERVOUS SYSTEM						
Brain, Brain Stem	(47)	(46)	(46)	(47)	(49)	(47)
Oligodendroglioma Malignant		1 (2%)				
Brain, Cerebellum	(47)	(46)	(46)	(47)	(49)	(47)
Osteosarcoma						
Brain, Cerebrum	(47)	(46)	(46)	(47)	(49)	(47)
Oligodendroglioma Malignant		1 (2%)				
Meninges, Osteosarcoma						
Peripheral Nerve	(0)	(0)	(0)	(0)	(1)	(1)
Spinal Cord	(0)	(0)	(0)	(0)	(1)	(1)
RESPIRATORY SYSTEM						
Lung	(48)	(47)	(46)	(48)	(50)	(48)
Adenocarcinoma, Metastatic, Harderian Gland					1 (2%)	
Adenocarcinoma, Metastatic, Mammary Gland						
Alveolar/Bronchiolar Adenoma	4 (8%)	5 (11%)	5 (11%)	6 (13%)	3 (6%)	1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple						
Alveolar/Bronchiolar Carcinoma	1 (2%)	3 (6%)		4 (8%)		3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple			1 (2%)		1 (2%)	
Fibrosarcoma, Metastatic, Skin						1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)				
Osteosarcoma						
Osteosarcoma, Metastatic, Brain, Cerebrum						
Osteosarcoma, Metastatic, Uncertain Primary Site						
Sarcoma, Metastatic, Skin						
Nose	(48)	(47)	(46)	(48)	(51)	(46)
Adenocarcinoma, Metastatic, Harderian Gland		1 (2%)				
Rhabdomyosarcoma, Metastatic, Harderian Gland						

SPECIAL SENSES SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Eye	(46)	(45)	(46)	(46)	(49)	(45)
Adenocarcinoma, Metastatic, Harderian Gland		1 (2%)				
Harderian Gland	(46)	(47)	(46)	(47)	(50)	(46)
Adenocarcinoma		1 (2%)				
Adenoma	2 (4%)	4 (9%)	8 (17%)	4 (9%)	3 (6%)	5 (11%)
Adenoma, Multiple		1 (2%)				
Rhabdomyosarcoma						
URINARY SYSTEM						
Kidney	(46)	(46)	(46)	(46)	(50)	(46)
Urinary Bladder	(46)	(46)	(46)	(46)	(49)	(45)
Hemangioma						
SYSTEMIC LESIONS						
Multiple Organs	*(48)	*(47)	*(47)	*(48)	*(51)	*(48)
Histiocytic Sarcoma	1 (2%)	2 (4%)		1 (2%)	1 (2%)	1 (2%)
Leukemia					1 (2%)	2 (4%)
Lymphoma Malignant	18 (38%)	18 (38%)	16 (34%)	15 (31%)	10 (20%)	14 (29%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE
FEMALE

AZTH/3TCH/NVPH/0

AZTM/3TCM/NVPM/0

AZTL/3TCL/NVPL/0

AZTH/3TCH/NFVH/0

AZTM/3TCM/NFVM/0

AZTL/3TCL/NFVL/0

Disposition Summary

	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Animals Initially in Study	49	48	48	26	49	50
Early Deaths						
Moribund Sacrifice	5	7	12	4	3	8
Natural Death	4	2	2	1	1	5
Survivors						
Moribund Sacrifice		2		2	5	4
Natural Death					1	
Terminal Sacrifice	39	34	31	16	37	30
Harvest	1	3	3	3	2	3
Animals Examined Microscopically	49	48	48	26	49	50

ALIMENTARY SYSTEM

Esophagus	(48)	(47)	(47)	(25)	(48)	(49)
Gallbladder	(45)	(45)	(45)	(25)	(47)	(46)
Intestine Large, Cecum	(45)	(46)	(45)	(25)	(47)	(45)
Sarcoma	1 (2%)					
Intestine Large, Colon	(45)	(46)	(46)	(25)	(47)	(46)
Intestine Large, Rectum	(45)	(46)	(46)	(25)	(47)	(46)
Sarcoma, Metastatic, Skin	1 (2%)					
Intestine Small, Duodenum	(45)	(46)	(46)	(25)	(47)	(45)
Adenoma	1 (2%)					
Intestine Small, Ileum	(45)	(46)	(46)	(25)	(47)	(45)
Polyp Adenomatous						
Intestine Small, Jejunum	(46)	(46)	(46)	(25)	(47)	(45)
Adenoma		1 (2%)				
Liver	(47)	(47)	(46)	(26)	(48)	(50)
Hemangiosarcoma		1 (2%)		1 (4%)		1 (2%)
Hemangiosarcoma, Metastatic, Spleen						
Hepatocellular Adenoma	2 (4%)	7 (15%)	4 (9%)	4 (15%)	7 (15%)	1 (2%)
Hepatocellular Adenoma, Multiple	1 (2%)	2 (4%)			1 (2%)	
Hepatocellular Carcinoma	2 (4%)	3 (6%)	1 (2%)		5 (10%)	3 (6%)
Hepatocellular Carcinoma, Multiple		1 (2%)				
Mesentery	(3)	(8)	(1)	(5)	(7)	(7)
Pancreas	(47)	(46)	(45)	(25)	(46)	(47)
Fibrous Histiocytoma						

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Sarcoma, Metastatic, Skin	1 (2%)					
Salivary Glands	(46)	(47)	(47)	(25)	(47)	(47)
Hemangiosarcoma		1 (2%)				
Stomach, Forestomach	(47)	(46)	(46)	(25)	(47)	(47)
Squamous Cell Papilloma	1 (2%)	1 (2%)		1 (4%)		1 (2%)
Squamous Cell Papilloma, Multiple						
Stomach, Glandular	(46)	(46)	(46)	(25)	(47)	(46)
Adenoma						
CARDIOVASCULAR SYSTEM						
Blood Vessel	(48)	(47)	(47)	(25)	(48)	(50)
Heart	(49)	(47)	(46)	(25)	(48)	(50)
Carcinoma, Metastatic, Lung						
ENDOCRINE SYSTEM						
Adrenal Cortex	(48)	(46)	(45)	(25)	(49)	(48)
Adenoma						
Subcapsular, Adenoma	2 (4%)					1 (2%)
Adrenal Medulla	(44)	(45)	(43)	(25)	(47)	(46)
Pheochromocytoma Benign				1 (4%)		
Islets, Pancreatic	(47)	(46)	(45)	(25)	(46)	(47)
Adenoma					1 (2%)	1 (2%)
Carcinoma		1 (2%)				
Parathyroid Gland	(41)	(44)	(38)	(21)	(42)	(42)
Pituitary Gland	(42)	(46)	(43)	(23)	(45)	(47)
Pars Distalis, Adenoma	5 (12%)	2 (4%)	3 (7%)	1 (4%)	4 (9%)	3 (6%)
Pars Intermedia, Adenoma						
Thyroid Gland	(47)	(45)	(46)	(25)	(48)	(47)
C-cell, Carcinoma			1 (2%)			
Follicular Cell, Adenoma						
Follicular Cell, Carcinoma					1 (2%)	
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(1)	(0)	(1)	(2)
Abdominal, Fibrosarcoma, Metastatic, Skin						

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Abdominal, Fibrous Histiocytoma					1 (100%)	
Abdominal, Sarcoma						
Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung						
Mediastinum, Carcinoma, Metastatic, Lung						
Thoracic, Sarcoma						
GENITAL SYSTEM						
Clitoral Gland	(46)	(46)	(46)	(25)	(47)	(46)
Ovary	(48)	(47)	(46)	(25)	(48)	(47)
Cystadenoma	2 (4%)	2 (4%)	1 (2%)	2 (8%)	1 (2%)	1 (2%)
Granulosa Cell Tumor Benign					1 (2%)	1 (2%)
Hemangioma						
Hemangiosarcoma			1 (2%)			
Luteoma	1 (2%)					
Sertoli Cell Tumor Benign						
Tubulostromal Adenoma		1 (2%)				
Yolk Sac Carcinoma					1 (2%)	
Uterus	(48)	(46)	(46)	(26)	(48)	(48)
Adenocarcinoma						
Granular Cell Tumor Benign						1 (2%)
Hemangiosarcoma	1 (2%)	1 (2%)			1 (2%)	
Polyp Stromal						1 (2%)
Sarcoma						1 (2%)
Sarcoma Stromal			1 (2%)			
HEMATOPOIETIC SYSTEM						
Bone Marrow	(48)	(46)	(46)	(25)	(47)	(47)
Hemangiosarcoma						
Hemangiosarcoma, Metastatic, Spleen					1 (2%)	
Lymph Node	(4)	(5)	(11)	(3)	(6)	(13)
Lumbar, Fibrous Histiocytoma					1 (17%)	
Mediastinal, Carcinoma, Metastatic, Lung						
Lymph Node, Mandibular	(47)	(47)	(47)	(25)	(48)	(48)
Adenocarcinoma, Metastatic, Harderian Gland						

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Lymph Node, Mesenteric Adenocarcinoma, Metastatic, Mammary Gland	(47)	(46)	(46)	(25)	(47) 1 (2%)	(48)
Fibrous Histiocytoma Hemangiosarcoma, Metastatic, Salivary Glands		1 (2%)				
Sarcoma Spleen	(48)	(47)	(47)	(25)	(48)	(50)
Hemangiosarcoma		1 (2%)	1 (2%)		3 (6%)	3 (6%)
Hemangiosarcoma, Metastatic, Salivary Glands		1 (2%)				
Hemangiosarcoma, Metastatic, Skin						1 (2%)
Thymus	(40)	(44)	(44)	(25)	(48)	(44)
Carcinoma, Metastatic, Lung Thymoma Benign						
INTEGUMENTARY SYSTEM						
Mammary Gland	(47)	(47)	(47)	(24)	(48)	(47)
Adenocarcinoma	1 (2%)		3 (6%)		3 (6%)	1 (2%)
Adenoma	1 (2%)	1 (2%)				1 (2%)
Skin	(49)	(47)	(47)	(25)	(48)	(49)
Hemangiosarcoma						1 (2%)
Trichoepithelioma				1 (4%)		
Ear, Hemangiosarcoma						
Subcutaneous Tissue, Fibrosarcoma		7 (15%)		1 (4%)		3 (6%)
Subcutaneous Tissue, Hemangioma						1 (2%)
Subcutaneous Tissue, Lipoma		1 (2%)			1 (2%)	
Subcutaneous Tissue, Sarcoma	1 (2%)	1 (2%)			1 (2%)	
MUSCULOSKELETAL SYSTEM						
Bone, Femur	(49)	(48)	(48)	(26)	(49)	(50)
Osteosarcoma		1 (2%)				
Skeletal Muscle	(1)	(2)	(0)	(0)	(0)	(0)
Fibrosarcoma, Metastatic, Skin		1 (50%)				
Hemangiosarcoma, Metastatic, Spleen						

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
NERVOUS SYSTEM						
Brain, Brain Stem	(47)	(46)	(46)	(25)	(48)	(47)
Oligodendroglioma Malignant						
Brain, Cerebellum	(47)	(46)	(46)	(25)	(48)	(47)
Osteosarcoma			1 (2%)			
Brain, Cerebrum	(47)	(46)	(46)	(25)	(48)	(47)
Oligodendroglioma Malignant						
Meninges, Osteosarcoma						1 (2%)
Peripheral Nerve	(1)	(1)	(0)	(0)	(0)	(0)
Spinal Cord	(1)	(1)	(0)	(0)	(0)	(0)
RESPIRATORY SYSTEM						
Lung	(48)	(47)	(46)	(25)	(47)	(50)
Adenocarcinoma, Metastatic, Harderian Gland						
Adenocarcinoma, Metastatic, Mammary Gland						
Alveolar/Bronchiolar Adenoma	2 (4%)	4 (9%)	2 (4%)	1 (4%)	3 (6%)	3 (6%)
Alveolar/Bronchiolar Adenoma, Multiple					1 (2%)	
Alveolar/Bronchiolar Carcinoma	4 (8%)	3 (6%)	2 (4%)	2 (8%)	3 (6%)	
Alveolar/Bronchiolar Carcinoma, Multiple						
Fibrosarcoma, Metastatic, Skin						
Hepatocellular Carcinoma, Metastatic, Liver						
Osteosarcoma	1 (2%)					
Osteosarcoma, Metastatic, Brain, Cerebrum						1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary Site						
Sarcoma, Metastatic, Skin	1 (2%)					
Nose	(49)	(47)	(48)	(26)	(47)	(48)
Adenocarcinoma, Metastatic, Harderian Gland						
Rhabdomyosarcoma, Metastatic, Harderian Gland			1 (2%)			

SPECIAL SENSES SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Eye	(45)	(45)	(45)	(25)	(47)	(45)
Adenocarcinoma, Metastatic, Harderian Gland						
Harderian Gland	(46)	(45)	(45)	(25)	(46)	(46)
Adenocarcinoma						
Adenoma	2 (4%)	4 (9%)	7 (16%)	2 (8%)	2 (4%)	5 (11%)
Adenoma, Multiple						
Rhabdomyosarcoma			1 (2%)			
URINARY SYSTEM						
Kidney	(47)	(47)	(48)	(25)	(47)	(47)
Urinary Bladder	(46)	(46)	(47)	(25)	(47)	(47)
Hemangioma						
SYSTEMIC LESIONS						
Multiple Organs	*(49)	*(48)	*(48)	*(26)	*(49)	*(50)
Histiocytic Sarcoma	2 (4%)		1 (2%)	1 (4%)		1 (2%)
Leukemia			1 (2%)			4 (8%)
Lymphoma Malignant	13 (27%)	13 (27%)	18 (38%)	9 (35%)	19 (39%)	9 (18%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE
FEMALE

SOLVENT to 0

Disposition Summary

Animals Initially in Study	64
Early Deaths	
Moribund Sacrifice	7
Natural Death	3
Survivors	
Moribund Sacrifice	6
Natural Death	1
Terminal Sacrifice	45
Harvest	2
Animals Examined Microscopically	64

ALIMENTARY SYSTEM

Esophagus	(62)
Gallbladder	(60)
Intestine Large, Cecum	(60)
Sarcoma	
Intestine Large, Colon	(60)
Intestine Large, Rectum	(60)
Sarcoma, Metastatic, Skin	
Intestine Small, Duodenum	(60)
Adenoma	
Intestine Small, Ileum	(60)
Polyp Adenomatous	
Intestine Small, Jejunum	(60)
Adenoma	
Liver	(61)
Hemangiosarcoma	2 (3%)
Hemangiosarcoma, Metastatic, Spleen	
Hepatocellular Adenoma	8 (13%)
Hepatocellular Adenoma, Multiple	1 (2%)
Hepatocellular Carcinoma	3 (5%)
Hepatocellular Carcinoma, Multiple	
Mesentery	(8)
Pancreas	(62)
Fibrous Histiocytoma	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Sarcoma, Metastatic, Skin	
Salivary Glands	(62)
Hemangiosarcoma	
Stomach, Forestomach	(62)
Squamous Cell Papilloma	
Squamous Cell Papilloma, Multiple	
Stomach, Glandular	(60)
Adenoma	
CARDIOVASCULAR SYSTEM	
Blood Vessel	(62)
Heart	(63)
Carcinoma, Metastatic, Lung	
ENDOCRINE SYSTEM	
Adrenal Cortex	(61)
Adenoma	1 (2%)
Subcapsular, Adenoma	
Adrenal Medulla	(60)
Pheochromocytoma Benign	1 (2%)
Islets, Pancreatic	(62)
Adenoma	3 (5%)
Carcinoma	
Parathyroid Gland	(54)
Pituitary Gland	(60)
Pars Distalis, Adenoma	6 (10%)
Pars Intermedia, Adenoma	
Thyroid Gland	(59)
C-cell, Carcinoma	
Follicular Cell, Adenoma	
Follicular Cell, Carcinoma	
GENERAL BODY SYSTEM	
Tissue NOS	(3)
Abdominal, Fibrosarcoma, Metastatic, Skin	

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Abdominal, Fibrous Histiocytoma	1 (33%)
Abdominal, Sarcoma	
Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (33%)
Mediastinum, Carcinoma, Metastatic, Lung	
Thoracic, Sarcoma	
GENITAL SYSTEM	
Clitoral Gland	(60)
Ovary	(60)
Cystadenoma	2 (3%)
Granulosa Cell Tumor Benign	
Hemangioma	
Hemangiosarcoma	
Luteoma	
Sertoli Cell Tumor Benign	
Tubulostromal Adenoma	
Yolk Sac Carcinoma	
Uterus	(62)
Adenocarcinoma	
Granular Cell Tumor Benign	
Hemangiosarcoma	
Polyp Stromal	
Sarcoma	
Sarcoma Stromal	1 (2%)
HEMATOPOIETIC SYSTEM	
Bone Marrow	(61)
Hemangiosarcoma	
Hemangiosarcoma, Metastatic, Spleen	
Lymph Node	(15)
Lumbar, Fibrous Histiocytoma	
Mediastinal, Carcinoma, Metastatic, Lung	
Lymph Node, Mandibular	(61)
Adenocarcinoma, Metastatic, Harderian Gland	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Lymph Node, Mesenteric	(60)
Adenocarcinoma, Metastatic, Mammary Gland	
Fibrous Histiocytoma	
Hemangiosarcoma, Metastatic, Salivary Glands	
Sarcoma	
Spleen	(62)
Hemangiosarcoma	2 (3%)
Hemangiosarcoma, Metastatic, Salivary Glands	
Hemangiosarcoma, Metastatic, Skin	
Thymus	(55)
Carcinoma, Metastatic, Lung	
Thymoma Benign	
INTEGUMENTARY SYSTEM	
Mammary Gland	(63)
Adenocarcinoma	6 (10%)
Adenoma	
Skin	(63)
Hemangiosarcoma	
Trichoepithelioma	
Ear, Hemangiosarcoma	
Subcutaneous Tissue, Fibrosarcoma	1 (2%)
Subcutaneous Tissue, Hemangioma	
Subcutaneous Tissue, Lipoma	
Subcutaneous Tissue, Sarcoma	2 (3%)
MUSCULOSKELETAL SYSTEM	
Bone, Femur	(64)
Osteosarcoma	
Skeletal Muscle	(1)
Fibrosarcoma, Metastatic, Skin	
Hemangiosarcoma, Metastatic, Spleen	

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE
FEMALE

SOLVENT to 0

NERVOUS SYSTEM

Brain, Brain Stem	(61)
Oligodendroglioma Malignant	
Brain, Cerebellum	(62)
Osteosarcoma	
Brain, Cerebrum	(62)
Oligodendroglioma Malignant	
Meninges, Osteosarcoma	
Peripheral Nerve	(1)
Spinal Cord	(1)

RESPIRATORY SYSTEM

Lung	(62)
Adenocarcinoma, Metastatic, Harderian Gland	1 (2%)
Adenocarcinoma, Metastatic, Mammary Gland	
Alveolar/Bronchiolar Adenoma	2 (3%)
Alveolar/Bronchiolar Adenoma, Multiple	
Alveolar/Bronchiolar Carcinoma	5 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple	
Fibrosarcoma, Metastatic, Skin	
Hepatocellular Carcinoma, Metastatic, Liver	
Osteosarcoma	
Osteosarcoma, Metastatic, Brain, Cerebrum	
Osteosarcoma, Metastatic, Uncertain Primary Site	1 (2%)
Sarcoma, Metastatic, Skin	
Nose	(62)
Adenocarcinoma, Metastatic, Harderian Gland	1 (2%)
Rhabdomyosarcoma, Metastatic, Harderian Gland	

SPECIAL SENSES SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Eye	(59)
Adenocarcinoma, Metastatic, Harderian Gland	
Harderian Gland	(60)
Adenocarcinoma	1 (2%)
Adenoma	5 (8%)
Adenoma, Multiple	
Rhabdomyosarcoma	
URINARY SYSTEM	
Kidney	(62)
Urinary Bladder	(60)
Hemangioma	1 (2%)
SYSTEMIC LESIONS	
Multiple Organs	*(64)
Histiocytic Sarcoma	3 (5%)
Leukemia	
Lymphoma Malignant	24 (38%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
-------------------------------------------	------------	------------	------------	------------------	------------------	------------------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	35	37	31	34	34	31
Total Primary Neoplasms	52	59	55	56	55	45
Total Animals with Benign Neoplasms	17	23	23	23	19	14
Total Benign Neoplasms	20	25	30	25	23	16
Total Animals with Malignant Neoplasms	26	30	20	26	28	23
Total Malignant Neoplasms	32	34	25	31	32	29
Total Animals with Metastatic Neoplasms		3		3	2	1
Total Metastatic Neoplasms		4		5	5	1
Total Animals with Malignant Neoplasms Uncertain Primary Site						
Total Animals with Neoplasms Uncertain-Benign or Malignant						
Total Uncertain Neoplasms						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE
FEMALE

AZTH/3TCH/NVPH/0

AZTM/3TCM/NVPM/0

AZTL/3TCL/NVPL/0

AZTH/3TCH/NFVH/0

AZTM/3TCM/NFVM/0

AZTL/3TCL/NFVL/0

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	33	34	34	19	35	38
Total Primary Neoplasms	46	60	49	27	61	49
Total Animals with Benign Neoplasms	17	22	16	10	20	18
Total Benign Neoplasms	20	26	17	13	22	21
Total Animals with Malignant Neoplasms	24	26	28	12	25	26
Total Malignant Neoplasms	26	34	32	14	39	28
Total Animals with Metastatic Neoplasms	1	2	1		2	2
Total Metastatic Neoplasms	3	3	1		2	2
Total Animals with Malignant Neoplasms Uncertain Primary Site						
Total Animals with Neoplasms Uncertain-Benign or Malignant						
Total Uncertain Neoplasms						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 11:50:26

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE
FEMALE

SOLVENT to 0

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	51
Total Primary Neoplasms	82
Total Animals with Benign Neoplasms	24
Total Benign Neoplasms	30
Total Animals with Malignant Neoplasms	41
Total Malignant Neoplasms	52
Total Animals with Metastatic Neoplasms	4
Total Metastatic Neoplasms	6
Total Animals with Malignant Neoplasms Uncertain Primary Site	1
Total Animals with Neoplasms Uncertain-Benign or Malignant	
Total Uncertain Neoplasms	

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors